Statement: Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.
Primary_evidence: Outcome Measurement:    Incidence of Treatment-emergent AE's   [Not Specified]   Time frame: 2 years Results 1:    Arm/Group Title: MM-111 + Herceptin   Arm/Group Description: MM-111 will be combined with Herceptin   MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV   Overall Number of Participants Analyzed: 16   Measure Type: Number   Unit of Measure: participants  16